CNS Neuroscience & Therapeutics

• Name: CNS Neuroscience & Therapeutics
• Publisher: Wiley‑Blackwell
• Founded: 1995 (as *CNS Drug Reviews*), rebranded in 2008
• Frequency: Bimonthly
• Scope: Clinical, experimental, and translational neuroscience
• Indexing: SCIE, Scopus, DOAJ, PubMed Central
• Impact Factor (JCR 2021): 7.035
• Estimated Impact Factor (2023–2024): ~4.8
• Scopus Impact Score: ~5.6
• H-index: ~99
• SJR: ~1.67
• Quartile: Q1 in Neuroscience, Pharmacology, Psychiatry

→ Summary: A well-regarded mid-to-high-tier journal with strong indexing and influence in translational neuroscience.

• Top Quartile Rankings in multiple domains (Neuroscience, Psychiatry, Pharmacology)
• Broad Translational Scope: From bench to bedside
• Reasonable Review Times: ~4–6 weeks to first decision
• Rigorous Peer Review: Thoughtful and constructive feedback
• Hybrid Open Access: Optional OA publication with some APC waivers

• Impact Factor Decline: Dropped from 7.0 (2021) to ~4.8 (2023)
• Moderate Selectivity: Acceptance rate around 25%
• Not Fully Open Access: Hybrid model may limit visibility
• Average Author Experience: Rated ~3/5 on SciRev

• Vs. Neuroscience & Biobehavioral Reviews: Higher impact but narrower in scope
• Vs. Psychiatry & Clinical Neurosciences: More clinically grounded, higher impact
• Vs. Nature Neuroscience / Neuron: Lower impact, but faster and more accessible

Ideal for:

• Translational neuroscience studies
• Therapeutic trials or drug mechanism research
• Authors seeking Q1 visibility with moderate speed

Less ideal for:

• High-impact basic science without therapeutic focus
• Work aiming for top-tier journals in basic neurobiology

*CNS Neuroscience & Therapeutics* is a solid, Q1-ranked journal ideal for translational neuroscience with therapeutic implications. It offers respectable impact, rigorous review, and broad indexing—though not suitable for breakthrough basic science aiming for elite impact.